| 1 |
34872842 | Retrospective Observational Real-World Outcome Study to Evaluate Safety Among Patients With Erectile Dysfunction (ED) With Co-Possession of Tadalafil and Anti-Hypertensive Medications (anti-HTN). | 2022 Jan |
2 |
| 2 |
35119252 | Effects of Tadalafil on skeletal muscle tissue: exploring interactions and novel mechanisms of action. | 2022 Feb 4 |
4 |
| 3 |
35135037 | The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment. | 2022 Feb 8 |
1 |
| 4 |
35457011 | Tadalafil and Steroid Hormones Interactions in Adipose, Bone and Prostate Tissues: Focus on Translational Perspectives. | 2022 Apr 11 |
2 |
| 5 |
35530128 | Free energy perturbation (FEP)-guided scaffold hopping. | 2022 Mar |
1 |
| 6 |
33718200 | New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. | 2021 |
1 |
| 7 |
34006491 | Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction. | 2021 May 15 |
2 |
| 8 |
34182826 | Tadalafil Reverses the Effect of Three-Dimensional Cell Culture System on Stem Cell Features in A549 and SK-MES-1. | 2021 Jul |
2 |
| 9 |
34440764 | Inhibition of Phosphodiesterase 3A by Cilostazol Dampens Proinflammatory Platelet Functions. | 2021 Aug 5 |
1 |
| 10 |
34471575 | Is Tadalafil an Effective Treatment Option for Interstitial Cystitis/Painful Bladder Syndrome? A Report of a Challenging Case. | 2021 Jul |
1 |
| 11 |
34471776 | On the Viability of Tadalafil-Based 18F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging. | 2021 Aug 24 |
4 |
| 12 |
34926008 | Bilateral Sequential Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). | 2021 Nov |
2 |
| 13 |
31654676 | The role of PDE5a in oocyte maturation of zebrafish. | 2020 Jan 15 |
1 |
| 14 |
32378365 | Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor? | 2020 Jul |
1 |
| 15 |
32401481 | Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist. | 2020 Jun 17 |
1 |
| 16 |
32502017 | Effect of daily tadalafil on reported outcomes in patients with erectile dysfunction and depressive symptoms: STROBE, a case-control study. | 2020 Jun 5 |
2 |
| 17 |
32542854 | Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study. | 2020 Aug |
1 |
| 18 |
32794708 | Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket. | 2020 Sep 10 |
2 |
| 19 |
30381900 | Q817G mutation in phosphodiesterase type 5: Conformational analysis and dissociation profile of the inhibitor Tadalafil. | 2019 Apr |
2 |
| 20 |
30414862 | Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. | 2019 Mar |
1 |
| 21 |
30747070 | Novel Pyrazolo[4, 3-c]Quinolin-3-One Derivatives as PDE5A Inhibitors. | 2019 |
1 |
| 22 |
30901259 | Tadalafil for the treatment of benign prostatic hyperplasia. | 2019 Jun |
1 |
| 23 |
31184029 | [Safety of tadalafil in patients with cardiovascular comorbidities]. | 2019 Apr |
1 |
| 24 |
31208060 | Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial. | 2019 Jun 15 |
2 |
| 25 |
31214178 | The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial. | 2019 |
1 |
| 26 |
31352710 | The Effect of Daily Low Dose Tadalafil on Cerebral Perfusion and Cognition in Patients with Erectile Dysfunction and Mild Cognitive Impairment. | 2019 Aug 31 |
1 |
| 27 |
31807426 | An open-label, single-arm pilot study to evaluate the efficacy of daily low dose tadalafil on depression in patients with erectile dysfunction. | 2019 Oct |
1 |
| 28 |
28830281 | Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. | 2018 Mar |
1 |
| 29 |
29089445 | Novel imaging of the prostate reveals spontaneous gland contraction and excretory duct quiescence together with different drug effects. | 2018 Mar |
1 |
| 30 |
29132113 | Fluorometric detection of protein-ligand engagement: The case of phosphodiesterase5. | 2018 Feb 5 |
1 |
| 31 |
29391766 | Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up. | 2018 Jan 21 |
1 |
| 32 |
29417353 | Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report. | 2018 Feb 7 |
2 |
| 33 |
29920215 | Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats. | 2018 Oct 1 |
2 |
| 34 |
30352768 | Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies - Still a possible treatment modality? | 2018 Nov |
2 |
| 35 |
30381311 | TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial. | 2018 Oct 30 |
1 |
| 36 |
30504628 | Characterization and Stability of Amorphous Tadalafil and Four Crystalline Polymorphs. | 2018 |
2 |
| 37 |
30548639 | Tadalafil: 15 years' journey in male erectile dysfunction and beyond. | 2018 Dec 13 |
1 |
| 38 |
27101805 | A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction. | 2017 Jul-Aug |
2 |
| 39 |
27338710 | Adulteration of herbal sexual enhancers and slimmers: The wish for better sexual well-being and perfect body can be risky. | 2017 Oct |
2 |
| 40 |
27581752 | In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors. | 2017 Oct |
1 |
| 41 |
28150511 | Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development. | 2017 Dec |
7 |
| 42 |
28566262 | Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic Right VEntricular size and function - A multi-center, double-blind, randomized, placebo-controlled clinical trial - SERVE trial - Rational and design. | 2017 Sep 15 |
1 |
| 43 |
28597769 | A systematic review of transition studies of pulmonary arterial hypertension specific medications. | 2017 Apr-Jun |
1 |
| 44 |
28603047 | Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro. | 2017 Sep 5 |
3 |
| 45 |
28932631 | Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). | 2017 |
2 |
| 46 |
28964803 | Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. | 2017 Dec 1 |
4 |
| 47 |
29202488 | Acute tadalafil administration increases plasma fatty acids without changes in the inflammatory response in healthy men. | 2017 |
1 |
| 48 |
29256125 | Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction. | 2017 |
1 |
| 49 |
25263347 | LC-ESI-MS/MS analysis of phosphodiesterase-5 inhibitors and their analogues in foods and dietary supplements in Korea. | 2016 |
1 |
| 50 |
26289211 | Transdermal delivery of tadalafil using a novel formulation. | 2016 Jun |
1 |